Chromocell Therapeutics Corp
For the period ended Dec 31, 2023. Filed Apr 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 16, 2024
PTHS$9.37+0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Changes in Stockholders’ Equity (Deficit)
STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIT
FOR THE YEAR ENDED DECEMBER 31, 2023 and 2022
| Common Shares | Par | Preferred Shares | Preferred Shares Par | Additional Paid-in Capital | Accumulated Deficit | Total Stockholders’ Deficit | |
|---|---|---|---|---|---|---|---|
| Balance, December 31, 2021 | — | $— | — | $— | $— | $(3,680,267) | $(3,680,267) |
| Fair value of shares issued in contribution agreement | 10,000,000 | 111 | 600,000 | 60 | 1,889,400 | — | 1,900,000 |
| Net contributions from Chromocell Corporation | — | — | — | — | 422,173 | — | 422,173 |
| Stock-based compensation | — | — | — | — | 110,146 | — | 110,146 |
| Net loss | — | — | — | — | — | (2,458,589) | (2,458,589) |
| Balance, December 31, 2022 | 10,000,000 | 1 | 600,000 | 60 | 2,421,719 | (6,138,856) | (3,706,537) |
| Stock-based compensation | — | — | — | — | 1,733,233 | — | 1,733,233 |
| Shares issued for extension of bridge loan | 18,892 | 2 | — | — | 428,398 | — | 428,400 |
| Shares issued for license | 384,226 | 38 | — | — | 2,225,695 | — | 2,225,733 |
| Shares issued for cash | 2,533,853 | 253 | — | — | 255,159 | — | 255,412 |
| Shares forfeited | (133,745) | (13) | — | — | 13 | — | — |
| Net loss | — | — | — | — | — | (7,380,793) | (7,380,793) |
| Balance December 31, 2023 | 3,914,338 | $391 | 600,000 | $60 | $7,074,646 | $(13,519,649) | $(6,444,552) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.